COVID-19 Booster Recommendations Extended to 16- and 17-year-olds
The following is attributable to CDC Director, Dr. Rochelle Walensky:
“Today, CDC is strengthening its booster recommendations and encouraging everyone 16 and older to receive a booster shot. Although we don’t have all the answers on the Omicron variant, initial data suggests that COVID-19 boosters help broaden and strengthen the protection against Omicron and other variants. We know that COVID-19 vaccines are safe and effective, and I strongly encourage adolescents ages 16 and 17 to get their booster if they are at least 6 months post their initial Pfizer vaccination series.”
At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for adolescents aged 16 and 17. More information will be available on CDC’s website soon.
Emergency Use Authorization
A new emergency use authorization (EUA) was released on 12/9/21 for the Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY. Pfizer vaccine supplied in a multiple dose vial with a purple cap is authorized for use to provide:
- a 2-dose primary series to individuals 12 years of age and older;
- a third primary series dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise;
- a single booster dose to individuals 16 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY; and
- a single booster dose to individuals 18 years of age and older who have completed primary vaccination with a different authorized COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.